HC Wainwright Issues Optimistic Estimate for MAZE Earnings

Key Points

• HC Wainwright raised its Q1 2026 EPS estimate for Maze to ($0.53) from ($0.62), reiterated a Buy rating and set a $110 price target while publishing updated multi-quarter and FY2026–FY2030 EPS projections.
• Maze reported ($0.65) EPS for the most recent quarter (Mar. 25), beating the consensus estimate of ($0.73) by $0.08.
• Analyst consensus remains a Buy with an average target of $66.44; shares opened at $28.09, trade in a 52‑week range of $6.71–$53.65, and the company has a market cap of about $1.4 billion.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) - Research analysts at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for shares of Maze Therapeutics in a research report issued on Tuesday, April 7th. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings of ($0.53) per share for the quarter, up from their previous forecast of ($0.62). HC Wainwright currently has a "Buy" rating and a $110.00 target price on the stock. HC Wainwright also issued estimates for Maze Therapeutics' Q2 2026 earnings at ($0.57) EPS, Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.56) EPS, FY2026 earnings at ($2.20) EPS, FY2028 earnings at ($2.51) EPS, FY2029 earnings at ($1.96) EPS and FY2030 earnings at ($0.20) EPS.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.08.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings reiterated a "sell (d)" rating on shares of Maze Therapeutics in a report on Thursday, January 22nd. Wedbush lifted their price objective on Maze Therapeutics from $43.00 to $58.00 and gave the company an "outperform" rating in a report on Monday, March 16th. JPMorgan Chase & Co. lifted their price objective on Maze Therapeutics from $52.00 to $58.00 and gave the company an "overweight" rating in a report on Tuesday, March 31st. BTIG Research reiterated a "buy" rating and set a $46.00 price objective on shares of Maze Therapeutics in a report on Wednesday, March 25th. Finally, Wall Street Zen upgraded Maze Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, March 28th. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $66.44.

Maze Therapeutics Price Performance

NASDAQ:MAZE opened at $28.09 on Thursday. Maze Therapeutics has a fifty-two week low of $6.71 and a fifty-two week high of $53.65. The stock has a market capitalization of $1.40 billion, a PE ratio of -8.70 and a beta of 5.16. The business's 50-day simple moving average is $43.17 and its 200-day simple moving average is $38.12.

Institutional Investors Weigh In On Maze Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Washington University raised its position in Maze Therapeutics by 33.3% in the 4th quarter. Washington University now owns 280,802 shares of the company's stock valued at $11,634,000 after buying an additional 70,121 shares during the last quarter. Frazier Life Sciences Management L.P. raised its stake in shares of Maze Therapeutics by 10.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company's stock worth $56,040,000 after purchasing an additional 438,274 shares in the last quarter. ArrowMark Colorado Holdings LLC bought a new stake in shares of Maze Therapeutics during the 3rd quarter worth approximately $14,135,000. Boothbay Fund Management LLC raised its stake in shares of Maze Therapeutics by 365.9% during the 3rd quarter. Boothbay Fund Management LLC now owns 351,875 shares of the company's stock worth $9,124,000 after purchasing an additional 276,345 shares in the last quarter. Finally, CW Advisors LLC bought a new stake in shares of Maze Therapeutics during the 2nd quarter worth approximately $371,000.

Insider Activity at Maze Therapeutics

In related news, SVP Amy Bachrodt sold 2,500 shares of Maze Therapeutics stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $29.44, for a total value of $73,600.00. Following the sale, the senior vice president owned 12,965 shares of the company's stock, valued at approximately $381,689.60. This trade represents a 16.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction that occurred on Thursday, January 29th. The shares were sold at an average price of $44.27, for a total value of $332,025.00. Following the completion of the sale, the insider directly owned 10,503 shares in the company, valued at approximately $464,967.81. This represents a 41.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 95,000 shares of company stock valued at $4,245,625.

About Maze Therapeutics

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.